U.S. markets closed

Tetra Bio-Pharma Inc. (JAM1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.1790-0.0050 (-2.72%)
At close: 8:04AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1840
Bid0.0000 x 4074100
Ask0.0000 x 2558200
Day's Range0.1790 - 0.1790
52 Week Range0.0790 - 0.3525
Avg. Volume14,281
Market Cap73.513M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

      Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing date of June 28, 2021. Through the Tetra partnership with Thorne HealthTech, a submission to the U.S. Food and Drug Administration for Generally Recognized as Safe (GRAS) is being pursued. GRAS st

    • PR Newswire

      Tetra Bio-Pharma Engages Christine Caron as Patient Partner

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.

    • CNW Group

      Tetra Bio-Pharma Accelerates REBORN1© Trial

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial.